Valiant OrganicsQ4 FY23

Valiant Organics Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹348.2P/E: 17.5Market Cap: ₹976 CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • FY '24 revenue guidance on a standalone basis is around INR 1,200 crores, implying 30%-35% growth.
  • Pharma Intermediates revenue expected to reach INR 55 crores in FY '24, phasing up to peak of INR 65-70 crores.
  • PAP (paracetamol) volumes targeted to scale from ~400 tons/month to 500 tons/month by Q2 FY '24, then progressively to 700-750 tons/month by year-end, aiming for INR 250-300 crores revenue.
  • Overall capacity utilization expected to increase in Sarigam unit from ~60% to 80-85% in the year, supporting agrochemical segment growth.
  • New product additions in chlorination and ammonolysis segments planned, supported by INR 100-110 crores annual capex, mostly for brownfield expansions and debottlenecking.
  • Volume growth is expected month-on-month, but exact percentages are uncertain; some segments like dyes remain subdued.
  • They target sustaining EBITDA margins around 20% in FY '24 with possible growth beyond 22-25% if significantly accretive products are added.

See what Valiant Organics management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • Currently, Valiant Organics Limited does not have any immediate plans to raise more debt.
  • Debt repayment is ongoing as per schedule, with about INR 40-45 crores expected to be repaid in the current financial year.
  • The company plans to fund its current capex primarily through internal accruals without raising additional debt for now.
  • If there is a future need to raise more debt, the company will consider that option at that time.
  • Regarding equity, a subsidiary named Valiant Advanced Sciences is planning to raise funds through a greenfield project and has given intimation of a possible public issue.
  • The parent company itself has not mentioned any equity fundraising in the current discussions.

See what Valiant Organics management said on order book — free account, 30 seconds.

Capex plans

Yes
  • Capex for FY '24 and FY '25 is projected around INR 100 crores to INR 110 crores annually, mainly for brownfield expansion, maintenance, and debottlenecking.
  • No major new projects like PAP or Pharma Intermediates; focus on adding new products, especially in chlorination and ammonolysis segments.
  • Some redevelopment and capacity improvement ongoing at Ahmedabad facility.
  • Debottlenecking at Sarigam chlorination plant considered, but no specific capex or capacity numbers disclosed yet.
  • Valiant Advanced Sciences, a subsidiary of Valiant Laboratories, plans a greenfield expansion project and is looking to raise funds, possibly through a public issue.
  • Capex mainly funded internally with no immediate plans to raise new debt, but options considered if needed.
  • Ongoing loan repayments expected around INR 40-45 crores next year, reducing overall debt.

Track Valiant Organics — get its next earnings analysis in your feed

How does Valiant Organics rank vs peers in Chemicals & Petrochemicals?

Pro feature
ThisValiant Organics
Rev 2Mar 3

How does Valiant Organics rank in Chemicals & Petrochemicals?

Compare Valiant Organics against every Chemicals & Petrochemicals company (Q4 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

Others in Chemicals & Petrochemicals this season

  • Seya Industries (Q2 FY27)

    Revenue from Operations (Net) for the quarter ended September 30, 2026: ₹0 lakhs (no sales reported). Key results statement takeaways from Seya Industries Ltd's

  • DCM Shriram Fine Chemicals (Q2 FY27)

    9,622.39 lakhs for the quarter ended September 30, 2025, indicating a year-on-year decrease of approximately 7.8%. Key results statement takeaways from DCM Shri

  • Dhariwalcorp (Q2 FY27)

    For the half year ended September 30, 2026, consolidated revenue from operations is ₹23,640.36 lakhs, up from ₹17,767.97 lakhs in the previous comparable…

  • Agastya Energy (Q2 FY27)

    For the quarter ended 30th September 2026, the consolidated revenue from operations was ₹625.15 lakhs, down from ₹4410.2 lakhs in the same quarter last year…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →